Asia is a significant growth opportunity for the pharmaceutical industry, with 50% of global clinical trials now occurring in the Asia Pacific region, particularly in China, Japan, and South Korea. These countries benefit from large patient populations and improving research infrastructure. However, there are serious concerns, as evidenced by the FDA issuing warning letters for CGMP violations in China, India, and Malaysia, with China being responsible for 21% of such letters. Additionally, Novartis faced potential suspension in Japan for alleged manipulation of clinical trial data, marking a notable regulatory action in the region.

The compliance gap in Asia is increasing, characterized by a fragmented regulatory landscape and intensified enforcement. Global pharmaceutical companies face challenges due to the disconnect between Western operating models and Asian regulatory realities. This blog explores the reasons behind ongoing compliance failures in Asia and highlights 2026 as a critical opportunity for improvement.

Regulatory Systems:

Asia’s regulatory landscape consists of numerous unique jurisdictions, each with distinct rules, timelines, and enforcement philosophies, contrasting with the EU’s centralized EMA and the US’s unified FDA systems.

In China, multiple agencies, such as the NMPA and provincial authorities, have overlapping jurisdictions for drug and device registration and GMP inspections, leading to significant interpretational variations. As a result, a single product marketed across five Asian countries must comply with distinct GMP standards, clinical trial regulations, and pharmacovigilance frameworks for each market, exacerbating the compliance burden.

• The Data Integrity Crisis

Data integrity is the most common GMP citation worldwide, including Asia, where PMDA publishes observations as warnings and technical references, with data integrity issues frequently among the top findings.

Data integrity failures often stem from inadequate documentation, failure to maintain audit trails, and insufficient oversight of computerized systems. In Asia’s fast-evolving digital landscape, many companies have adopted electronic systems without proper validation, leading to audit trail gaps that attract regulatory scrutiny.

• Enforcement Divergence and the “Two-Tier” Reality

A persistent challenge in Asian markets is the uneven enforcement of regulations. China and Singapore have modernized their inspection regimes, aligning with international standards, whereas other markets remain unpredictable. South Korean biotech leaders criticize rigid regulations that push clinical trials abroad, while India faces slow approvals and weak infrastructure, potentially trailing China in the pharma value chain. This results in a two-tier compliance environment, where multinational companies face intense scrutiny, contrasting with smaller local players operating under different standards, leading to market distortions and complicating global supply chains.

• Language and Cultural Gaps

Language barriers pose compliance risks due to regulatory documents often being in local languages, with English translations potentially losing nuances. Cultural differences impact communication; for instance, Asian regulators may provide indirect negative feedback, which Western companies may misinterpret, while assertive questioning from Western firms may come off as confrontational in hierarchical cultures.

• The Supply Chain Blind Spot

China’s revised Medical Device GMP, effective November 1, 2026, enhances regulatory oversight on contract manufacturing and outsourced activities, emphasizing lifecycle quality management. This change highlights a regional trend where regulators seek comprehensive visibility into the entire supply chain, including suppliers and logistics. Global companies are now held fully accountable for their partners’ compliance under these regulations, regardless of direct control.

• Data Privacy and Cross-Border Transfer Complexities

APAC privacy compliance varies significantly across jurisdictions, complicating governance and increasing regulatory and operational risks due to cross-border data movement and localization requirements. Key frameworks are highlighted.

For pharmaceutical companies engaged in multinational clinical trials, fragmented legal requirements present substantial operational challenges. Data transitions from India to a global safety database may adhere to one legal framework while contravening another. As of January 2026, Singapore’s PDPC reported 2,672 complaints related to the PDPA, with prominent issues concerning non-compliance with data minimization, unlawful collection, and improper use and disclosure. The consequences of non-compliance include fines, suspension of data transfers, and potential damage to patient trust.

How to Fix Compliance in 2026

• Stop Treating Asia as a Monolith

The primary error made by global pharmaceutical companies is the implementation of a uniform compliance strategy across Asia, ignoring the distinct priorities and enforcement approaches of regulators like China’s NMPA, India’s CDSCO, Japan’s PMDA, and Singapore’s HSA. To rectify this, companies should create tailored compliance strategies, appoint local regulatory experts for key markets, and deepen their comprehension of both explicit regulations and implicit expectations from regulators.

• Invest in Local Regulatory Intelligence

Compliance in clinical trials is critically dependent on awareness of regulatory changes. In India, the January 2026 NDCT amendments reduced clinical trial review timelines from 90 to 45 working days and introduced a “prior intimation” process for specific studies. Companies unaware of these amendments risk non-compliance with ongoing requirements for high-risk categories. In China, new Medical Device GMP regulations added standalone chapters on Quality Assurance and related topics, urging manufacturers to adapt their quality systems before the November 1, 2026 deadline to avoid inspection issues and registration delays. To navigate these changes effectively, companies should establish regulatory intelligence functions, subscribe to local alerts, consult local legal counsel, and engage with industry associations in relevant markets.

• Prioritize Data Integrity from the Start

Data integrity failures indicate systemic quality culture weaknesses, often due to poor training, lack of oversight in electronic systems, and production target pressures compromising documentation quality. To address these issues, it’s essential to adopt ALCOA+ principles as standard practice, validate computerized systems, perform regular internal audits focused on data integrity, and set clear consequences for documentation failures.

• Build Local Expertise Through Strategic Partnerships

To navigate Asia’s compliance landscape effectively, it is crucial to partner with local experts such as CROs, regulatory consultants, and quality advisors. These professionals possess extensive experience with regulators and can forewarn about potential issues. For instance, Singapore’s HSA has implemented a new procedure that allows companies to request GMP inspections for overseas drug substance manufacturing sites that lack compliance evidence at submission. Success in this landscape hinges on finding qualified local partners, establishing clear quality agreements, and conducting regular joint audits to maintain alignment.

• Conduct Mock Inspections and Gap Assessments

The most successful companies proactively prepare for regulatory inspections through mock inspections conducted by experienced consultants. These simulations help identify documentation and process gaps and enhance staff confidence. It is recommended to schedule regular mock inspections for each manufacturing site and major regulatory market, using the findings to improve operations before actual inspections.

• Embed Compliance into Supply Chain Contracts

Regulators are now holding marketing authorization holders accountable for the compliance of their partners, necessitating that supply chain contracts clearly outline regulatory obligations. To address this, it is essential to include specific compliance clauses in all CMO and supplier contracts, require regular audit rights, establish clear notification requirements for changes impacting regulatory status, and document oversight activities.

How Zenovel Helps Global Pharma Companies Achieve Compliance in Asia

Zenovel assists pharmaceutical companies in navigating Asia’s regulatory complexities, leveraging over extensive years of experience and a history of servicing clients around the countries to ensure compliance success through local knowledge and a global perspective.

Our Asia Compliance Services:

Asia’s pharmaceutical market presents significant growth opportunities for compliant companies. Our consultancy boasts deep local expertise with various Asian regulators and supports our clients globally through a proven methodology that aligns with ICH and GMP standards. We provide end-to-end support, addressing challenges from inspections to compliance. Companies must invest in local regulatory knowledge, integrate data integrity into their cultures, collaborate with experts, and proactively prepare for inspections to succeed by 2026 amid a fragmented regulatory landscape and increasing scrutiny.

Ready to Strengthen Your Compliance in Asia? Contact Zenovel to leverage our regulatory and GxP expertise for navigating Asia’s compliance landscape. With extensive experience in India, China, Japan, South Korea, Singapore, and a history of aiding global pharmaceutical companies in achieving compliance, Zenovel is your reliable partner for pharmaceutical quality and regulatory excellence.